News

404

Tomas Hode, Wei R. Chen, Siu Kit “Samuel” Lam T Cell Paper Publication

Tomas Hode, Wei R. Chen, Siu Kit “Samuel” Lam T Cell Paper Publication

Immunophotonics would like to congratulate Ashley Hoover and Kaili Liu lead authors from the University of Oklahoma and to the co-authors Tomas Hode, Wei Chen, and Sui Kit “Samuel” Lam on the T-Cell Paper publication in Clinical and Translational Medicine July 2022 issue. Check out this pivotal publication on how immunological remodeling of T-cells can...

Immunophotonics Announces First Patient Dosed in Phase 2a Clinical Trial of IP-001 in advanced solid tumor indications

Immunophotonics announced that the first patient has been dosed in the phase 2a portion of its Swiss clinical trial for treatment of multiple selected cancer indications. This multicenter clinical trial is designed to evaluate the immunologically mediated anticancer effects of intratumorally injecting the company’s lead asset, IP-001, following thermal ablation in patients with advanced solid...

Immunophotonics HEC-TV Interview

Immunophotonics was interviewed by HEC-TV, St. Louis on our lead asset IP-001. Immunophotonics would not be where they are today if it weren’t for the entire team, many of whom are featured in this segment. Great Job Abby Delawder, Chun Fung (Johnny) Wong, Siu Kit (Samuel) Lam, Lu Alleruzzo, Tomas Hode. To View Click Here

Swiss Biotech Day May 2-3, 2022

The Immunophotonics Team is thrilled to announce that Dr. Theresa Visarius of Immunophotonics Switzerland (IPS Biopharma) will be presenting at the Swiss Biotech Day on Tuesday, May 3rd in the Clinical Stage Development Company category.

US Oncology Research BioTech Day, Early Development Program Summit

Samuel Lam, PhD, Vice President of Science and Research at Immunophotonics, Inc. and Markus Joerger, MD, PhD, Clinical Trial Principal Investigator spoke at the US Oncology Research BioTech Day, Early Development Program (EDP) Summit in Coronado, California, on April 27, 2022 at 1:00 p.m. in the Glorietta Room. Immunophotonics thanks Dr. Dan Von Hoff and...

European Conference on Interventional Oncology (EICO 2022) April 24–27, 2022

Interested in learning how Immunophotonics, Inc. continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into a systemic immunotherapy against cancer. Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the European Conference on Interventional Oncology (EICO 2022) in Vienna, Austria April 24 – 27, 2022. This...

Immunophotonics Announces Appointment of Miguel Zubizarreta to Its Board of Directors

Immunophotonics has strengthened its leadership with the appointment of Miguel Zubizarreta to its Board of Directors. Mr. Zubizarreta, a tech pioneer and serial entrepreneur, joins a biotech-savvy slate of experts currently serving on the Board of Immunophotonics and brings a complementary set of proficiencies to the Board’s wealth of expertise within the pharmaceutical industry. Read...

American Association for Cancer Research (AACR) Annual Meeting, April 8 – 13, 2022

Look for Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. in New Orleans at the American Association for Cancer Research (AACR) Annual Meeting 2022 through Wednesday, April 13th. He will be catching up on the latest advances in cancer science and medicine. The AACR Annual Meeting highlights the work of the best minds...

Scroll to top